Eli Lilly reported quarterly results that significantly exceeded analyst expectations, driven by soaring sales of its weight-loss drug Zepbound and diabetes treatment Mounjaro. The company raised its full-year revenue guidance by $2 billion and also increased its adjusted profit forecast. The strong performance underscores the surging demand for GLP-1 receptor agonists, a class of drugs that has become a major growth driver for the pharmaceutical industry. Lilly’s shares rose in after-hours trading as investors cheered the upbeat outlook.
Market Outlook
Eli Lilly’s stock appears poised for further gains in the short term, supported by robust demand for its key products and an upgraded guidance. However, competition in the GLP-1 market may introduce volatility, so investors should monitor developments closely.
Source: CNBC Business
Disclaimer: this content is informational analysis only and does not constitute investment advice.
